Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib, Toripalimab and Celecoxib in MSS Colorectal Cancer
NCT05933980Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2023
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib, toripalimab, celecoxib in colorectal cancer (CRC), sponsored by Sun Yat-sen University. Started Dec 2023; status: recruiting.
02
Drugs
regorafenibtoripalimabcelecoxib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05933980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05933980.